Search Results - prostate+cancer

6 Results

Sort By:

Compounds that Interfere with the Androgen Receptor Complex

Abstract: Investigators at the National Institutes of Health (NIH) have discovered compounds that have potential as novel anti-androgen therapeutics. The immunophilin protein FKBP52 is part of a protein complex that helps fold the androgen receptor (AR) protein, a target for treating prostate cancer, and enhances its activity. Disruption of the FKPB52-AR...

Published: 4/8/2024 | Inventor(s): Leonard Neckers, Jane Trepel Neckers, Yeong Kim, Aki Iwai, Yangmin Ning, Marc Cox, Johanny Meneses De Leon, Heather Balsiger, Robert Fletterick

Keywords(s): androgen receptor protein, DIABETES, PROSTATE CANCER

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology

Human T Cell Receptors for Treating Cancer

Abstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit...

Published: 4/8/2024 | Inventor(s): Richard Morgan, Nachimuthu Chinnasamy, Steven Rosenberg

Keywords(s): COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer

Abstract: The development of more targeted means of treating cancer is vital. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of antibodies or T cells that recognize the...

Published: 4/8/2024 | Inventor(s): Lauren Wood, Jay Berzofsky, Brenda Roberson, Masaki Terabe

Keywords(s): BREAST CANCER, CANCER VACCINE, Immunotherapy, PROSTATE CANCER

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines

Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment

Abstract: Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy,...

Published: 4/8/2024 | Inventor(s): Berkley Gryder, Adegboyega Oyelere, Eric Raftery, Subhasish Tapadar, Nicholas Aboreden, William Figg

Keywords(s): Androgen Deficiency Disorders, Androgen dysfunctional Disorders, Androgen Receptor, Androgen Receptor Inverse Agonists, Anti-androgens, AR, ARIA, BREAST CANCER, Georgia Institute of Technology, GIT, Gryder, Hyperandrogenism, PROSTATE CANCER

Category(s): Application > Therapeutics, TherapeuticArea > Endocrinology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Treatment of Prostate Cancer Using Anti-androgen Small Molecules

Abstract: Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target...

Published: 4/8/2024 | Inventor(s): Jane Trepel Neckers, Yeong Kim, Sunmin Lee, Vineet Kumar, Sanjay Malhotra

Keywords(s): Antiandrogen, castrate resistant, CRPC, PROSTATE CANCER, small molecule, steroid hormone receptor.

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN

PTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to...

Published: 4/8/2024 | Inventor(s): Michael Quon, Derek Leroith

Keywords(s): ADENOCARCINOMA, BREAST CANCER, CA1XXX, CANCER, CAXXXX, CCXXXX, Cells, CHARACTERIZATION, Chromosome 7, monosomy, CXXXXX, Deletion 7, endometrial, Expressing, Gene, IGF1R, lung cancer, MEN 1, OVARIAN CANCER, PROSTATE CANCER, PTEN, tumor suppressor, Zollinger-Ellison syndrome

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials